Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma

Hepatology Research

Volumn 43, Issue 9, 2013, Pages 959-969

  Kumagai, Arisa ^a,b   Fukushima, Junichi ^a,c   Takikawa, Hajime ^a   Fukuda, Toshio ^b   Fukusato, Toshio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

Author keywords

Chemoembolization; Farnesoid X receptor; Hepatocellular carcinoma; Proliferation marker

Indexed keywords

FARNESOID X RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA;

ARTICLE; CANCER CELL; CELL NUCLEUS; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; WESTERN BLOTTING;

EID: 84883501278     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12047     Document Type: Article

References (29)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
2. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191.
3. Forman BM, Goode E, Chen J etal. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-693.
4. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, van Erpecum KJ. Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 2010; 1801: 683-692.
5. Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-1125.
6. Koutsounas I, Giaginis C, Theocharis S. Farnesoid X Receptor (FXR) from normal to malignant state. Histol Histopathol 2012; 27: 835-853.
7. Huang W, Ma K, Zhang J etal. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006; 312: 233-236.
8. Chen WD, Wang YD, Zhang L etal. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 2010; 51: 953-962.
9. Chen WD, Wang YD, Meng Z, Zhang L, Huang W. Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim Biophys Acta 2011; 1812: 888-892.
10. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28: 940-946.
11. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007; 67: 863-867.
12. Journe F, Laurent G, Chaboteaux C etal. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat 2008; 107: 49-61.
13. Lee JY, Lee KT, Lee JK etal. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br J Cancer 2011; 104: 1027-1037.
14. Liu N, Meng Z, Lou G etal. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol Endocrinol 2012; 26: 775-785.
15. Martinez-Becerra P, Vaquero J, Romero MR etal. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm 2012; 9: 1693-1704.
16. Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 2011; 338: 12-21.
17. Theise ND, Gurado MP, Franceschi S, Hytiroglou P, Kudo M. WHO Classification of Tumours of the Digestive System, 4th edn. Lyon: International Agency for Research on Cancer (IARC), 2010.
18. De Gottardi A, Touri F, Maurer CA etal. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 2004; 49: 982-989.
19. Lax S, Schauer G, Prein K etal. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer 2012; 130: 2232-2239.
20. Zhang Y, Gong W, Dai S etal. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res 2012; 10: 516-522.
21. Zhong XY, Yu JH, Zhang WG etal. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 2012; 493: 44-51.
22. Fiorucci S, Antonelli E, Rizzo G etal. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127: 1497-1512.
23. Fickert P, Fuchsbichler A, Moustafa T etal. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009; 175: 2392-2405.
24. Li J, Zhang Y, Kuruba R etal. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol 2011; 80: 191-200.
25. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 2006; 66: 10120-10126.
26. Fujino T, Takeuchi A, Maruko-Ohtake A etal. Critical role of farnesoid X receptor (FXR) for hepatocellular carcinoma cell proliferation. J Biochem 2012; 152: 577-586.
27. Journe F, Durbecq V, Chaboteaux C etal. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat 2009; 115: 523-535.
28. Monte MJ, Serrano MA, Herraez E etal. Chemoresistance can be induced by bile acid-independent activation of FXR in liver and intestinal cancer cells. Hepatology 2011; 54: 713-714.
29. Xiao EH, Li JQ, Huang JF. Effect of preoperative transcatheter arterial chemoembolization on proliferation of hepatocellular carcinoma cells. World J Gastroenterol 2007; 13: 4509-4513.